Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.75B P/E - EPS this Y 256.80% Ern Qtrly Grth -
Income -1.71M Forward P/E 45.63 EPS next Y 94.80% 50D Avg Chg 12.00%
Sales 813.81M PEG -0.09 EPS past 5Y - 200D Avg Chg 45.00%
Dividend N/A Price/Book 12.06 EPS next 5Y -357.00% 52W High Chg -14.00%
Recommedations 2.10 Quick Ratio 1.73 Shares Outstanding 165.22M 52W Low Chg 113.00%
Insider Own 0.51% ROA -0.38% Shares Float 107.62M Beta 0.38
Inst Own 100.95% ROE -0.41% Shares Shorted/Prior 11.33M/12.63M Price 29.20
Gross Margin 50.23% Profit Margin -0.21% Avg. Volume 1,634,129 Target Price 27.32
Oper. Margin 7.39% Earnings Date Aug 6 Volume 1,707,063 Change 0.90%
About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc. News
07/24/24 Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024
07/18/24 Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med
06/21/24 Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds?
06/18/24 Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
05/29/24 3 Sorry Pharma Stocks to Sell in May While You Still Can
05/23/24 It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay Rise This Year
05/17/24 Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/15/24 Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
05/11/24 Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
05/10/24 ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
05/10/24 ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/09/24 Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
05/09/24 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
05/09/24 ACADIA Pharmaceuticals Inc (ACAD) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue ...
05/08/24 Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
05/08/24 Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
05/06/24 Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
05/04/24 Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)
04/29/24 Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
04/28/24 ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago
ACAD Chatroom

User Image Downsiderisk Posted - 3 hours ago

$ACAD $13 call by the end of August. The bottom is about to fall out of this boat!

User Image RichieMagaoneCarter Posted - 6 hours ago

$ACAD great close Yardies! Have a blessed weekend and Down boy please don’t loose it this weekend after looking at your 14 shorts

User Image zeustony88 Posted - 6 hours ago

$ACAD How stupid are we?

User Image Downsiderisk Posted - 6 hours ago

$ACAD

User Image zeustony88 Posted - 6 hours ago

$ACAD Now these clowns talking about pulling rugs. Whats next a titanic sinking gif?

User Image Downsiderisk Posted - 7 hours ago

$ACAD rug pull is right staggy! I love hearing from these bull clowns because these are the same morons that will be crawling back in their holes soon!! Ask yourselves this morons! What’s driving this run? New products-no, Approvals-no, line extensions-no so then what?! Maybe revenues that meet expectations or not coming August 6th? I wouldn’t count on a run based on that knowledge! I’ll have the last laugh you idiots when the shorts come in!!

User Image Staggyy Posted - 9 hours ago

$ACAD I smell rug pull

User Image Ham1198 Posted - 9 hours ago

$ACAD same as yesterday. Close flat

User Image kiwitc2000 Posted - 10 hours ago

$ACAD Looks like it wants to pull back a little before taking the leap? Can we get past 21 next week?

User Image zeustony88 Posted - 10 hours ago

$ACAD Any chance Downriskclown stops posting when we hit $25?

User Image RichieMagaoneCarter Posted - 10 hours ago

$ACAD next stop on the weekly 21.83. Let’s go

User Image SBL71 Posted - 12 hours ago

$ACAD steady climb. 👍

User Image RichieMagaoneCarter Posted - 12 hours ago

$ACAD let’s break that 19.28 today for a real break out

User Image BobBijawk Posted - 12 hours ago

$ACAD Fact almost every stock baker brothers have had in their top 5 of holdings has made them massive returns. MDGL ACAD BGNE SGEN and a bunch of other past winners. Julian and Felix one is a finance guru the other is a science and oncology guru. I have no doubt this will double within next year or two. Dont listen to the resident clown he is about as knowlegable as the doorman at my high rise condo.

User Image BobBijawk Posted - 13 hours ago

$ACAD downsider be like this when hes looking at his acad puts

User Image Downsiderisk Posted - 22 hours ago

$ACAD this stock has fewer legs than SBL’s wife.

User Image Downsiderisk Posted - 1 day ago

$ACAD heard today of another Exodus at Acadia. Employees are tired of false hope and they’re bailing out from Stevie’s Bs!

User Image Ham1198 Posted - 1 day ago

$ACAD I was close

User Image Ham1198 Posted - 1 day ago

$ACAD will probably close RED

User Image Stocks2Retire Posted - 1 day ago

$ACAD breaking out of the cup and handle .. on its way to 20+

User Image zeustony88 Posted - 1 day ago

$ACAD Do your research, don't listen to Downsideclown, and then add more shares. Easy $$

User Image RonIsWrong Posted - 1 day ago

$ACAD continuing with a higher high here. calls up nicely from that bottom

User Image Downsiderisk Posted - 1 day ago

$ACAD I hope you all buy again!!! I’m ready to short this pig again soon!

User Image G101SPM Posted - 1 day ago

$ACAD $18.44 bid. SELL/TAKE PROFIT on 50% of remaining position with intent to REVISIT and retain original allocation. * DAC (dollar average cost) $15.74 (6.27.24). EXIT $23.00. Partial sell as precaution to maintain 70% portfolio cash reserves- see postings under title. * Click SEARCH (magnifying glass) icon on our landing page to review postings.

User Image BobBijawk Posted - 1 day ago

$ACAD if you think this going back to 15 downsider you crazy

User Image StockConsultant Posted - 1 day ago

$ACAD Acadia Pharmaceuticals stock watch for a bottom breakout above 19.28, nice upside price gap at https://stockconsultant.com/?ACAD

User Image Downsiderisk Posted - 2 days ago

$ACAD

User Image Jusprag24 Posted - 2 days ago

$ACAD I think it's time to buy this stock again

User Image Stock_Titan Posted - 2 days ago

$ACAD Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024 https://www.stocktitan.net/news/ACAD/acadia-pharmaceuticals-to-announce-second-quarter-financial-results-ojxg4bm16p34.html

User Image BobBijawk Posted - 2 days ago

$ACAD smokin them shorts wha sapennin downsider. I am an east sider essay.

Analyst Ratings
Morgan Stanley Overweight Jul 12, 24
BMO Capital Outperform Jun 27, 24
RBC Capital Outperform Jun 25, 24
B of A Securities Neutral May 10, 24
HC Wainwright & Co. Buy May 9, 24
Citigroup Buy May 9, 24
Stifel Hold May 9, 24
Cantor Fitzgerald Overweight May 9, 24
Mizuho Neutral May 9, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
DAVIS STEPHEN CEO CEO Jan 06 Sell 29.96 3,732 111,811 96,521 01/09/24
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 29.96 731 21,901 30,949 01/09/24
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 29.96 590 17,676 46,901 01/09/24
Kihara James Principal Accounting.. Principal Accounting Officer Dec 15 Sell 28.30 2,000 56,600 11,025 12/15/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Nov 17 Sell 22.64 4,960 112,294 30,393 11/21/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Nov 17 Sell 22.64 5,108 115,645 20,486 11/21/23
Kihara James Principal Accounting.. Principal Accounting Officer Nov 17 Sell 22.64 1,985 44,940 13,025 11/21/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Oct 05 Sell 21.96 16,369 359,463 45,857 10/06/23
DAVIS STEPHEN CEO CEO Oct 05 Sell 21.96 51,563 1,132,323 89,131 10/06/23
Kihara James Principal Accounting.. Principal Accounting Officer Sep 15 Sell 25.88 2,000 51,760 10,778 09/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Aug 21 Sell 28.997 10,000 289,970 15,682 08/23/23
DAVIS STEPHEN CEO CEO Jul 14 Option 20.77 100,000 2,077,000 136,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 14 Sell 30.04 100,000 3,004,000 36,695 07/18/23
DAVIS STEPHEN CEO CEO Jul 11 Sell 25.03 71,602 1,792,198 36,695 07/13/23
Brege Laura Director Director Jun 12 Sell 24.868 4,500 111,906 13,502 06/14/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 25.02 974 24,369 22,824 06/12/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 23,798 06/12/23
BAKER BROS. ADVISORS LP Director Director May 22 Buy 25.22 896,522 22,610,285 39,317,673 05/24/23
BAKER BROS. ADVISORS LP Director Director May 22 Option 17.01 25,000 425,250 38,620,261 05/24/23
Kihara James Principal Accounting.. Principal Accounting Officer May 17 Sell 22.5 5,947 133,808 11,144 05/19/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer May 17 Sell 22.5 15,310 344,475 21,905 05/19/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial May 17 Sell 22.5 14,869 334,552 24,356 05/19/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 21.18 917 19,422 25,513 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 21.18 548 11,607 9,487 05/02/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Option 0 1,567 10,035 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Sell 21.18 7,806 165,331 108,297 05/02/23
DAVIS STEPHEN CEO CEO Apr 29 Option 0 15,625 116,103 05/02/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 07 Sell 18.14 523 9,487 5,197 04/11/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 05 Sell 18.16 1,751 31,798 8,468 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Apr 05 Sell 18.16 701 12,730 4,231 04/07/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Apr 05 Sell 18.16 1,916 34,795 7,477 04/07/23
DAVIS STEPHEN CEO CEO Apr 05 Sell 18.16 8,582 155,849 100,478 04/07/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 05 Sell 18.16 1,456 26,441 23,425 04/07/23
Kihara James Principal Accounting.. Principal Accounting Officer Feb 23 Sell 18.78 350 6,573 2,923 02/27/23
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Feb 23 Sell 18.78 577 10,836 4,118 02/27/23
DAVIS STEPHEN CEO CEO Feb 23 Sell 18.78 3,851 72,322 91,727 02/27/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Feb 23 Sell 18.78 803 15,080 20,108 02/27/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Feb 23 Sell 18.78 461 8,658 5,195 02/27/23
BAKER BROS. ADVISORS LP Director Director Jan 12 Option 5.22 30,000 156,600 38,484,981 01/17/23
DAVIS STEPHEN CEO CEO Jan 06 Sell 17.13 3,904 66,876 84,633 01/10/23
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Jan 06 Sell 17.13 532 9,113 4,549 01/10/23
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Jan 06 Sell 17.13 589 10,090 18,697 01/10/23
Stankovic Srdjan R. President President Oct 15 Sell 15.81 1,326 20,964 56,831 10/18/22
DAVIS STEPHEN CEO CEO Oct 15 Sell 15.81 2,804 44,331 79,009 10/18/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Option 0 1,893 3,995 06/10/22
Schneyer Mark C. EVP, Chief Financial.. EVP, Chief Financial Officer Jun 08 Sell 17.91 653 11,695 3,342 06/10/22
DAVIS STEPHEN CEO CEO Apr 29 Sell 18.18 5,483 99,681 75,875 05/03/22
Stankovic Srdjan R. President President Apr 29 Sell 18.18 2,865 52,086 55,188 05/03/22
KIM AUSTIN D. EVP,General Counsel,.. EVP,General Counsel, Secretary Apr 29 Sell 18.18 894 16,253 16,742 05/03/22
Teehan Brendan EVP, COO, Head of Co.. EVP, COO, Head of Commercial Apr 29 Sell 18.18 552 10,035 3,437 05/03/22